ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology company - Pretax loss in year to March 31 narrows to £11.1 million from £13.4 million loss a year prior. Research & development costs fall to £8.1 million from £9.5 million, with general & administrative costs at £3.6 million versus £3.7 million. Revenue drops to £403,000 from £257,000.

Chair Iain Ross says: ‘During the period tough decisions have been taken, the business model re-focussed and the board and management team strengthened in line with our future goals.’

Following a strategic review in January, company now fully focused on expanding its proprietary customisable exosomes platform.

‘Personally, I have been most impressed with the competence, resilience and determination of the ReNeuron team and look forward to driving the business forward, executing a realistic plan and achieving meaningful milestones over the next 12 months,’ Ross adds.

Current stock price: 27.45 pence

12-month change: down 75%

Copyright 2022 Alliance News Limited. All Rights Reserved.